Reynolds Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Reynolds Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,100	Closed	-$516K	–	163
2015 Q4	$516K	Buy	+4,100	New	+$495K	0.56%	49
2015 Q3	–	Sell	-6,800	Closed	-$840K	–	198
2015 Q2	$840K	Buy	6,800 +300	+5%	+$37.8K	0.82%	23
2015 Q1	$767K	Buy	6,500 +2,700	+71%	+$323K	0.67%	30
2014 Q4	$451K	Buy	3,800 +2,000	+111%	+$225K	0.38%	92
2014 Q3	$202K	Buy	+1,800	New	+$171K	0.2%	201

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Reynolds Capital Management's VRTX Position: Q1 2016 in Review

Reynolds Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 4,100 shares — an estimated $516K sold.

Reynolds Capital Management first reported a position in VRTX in Q3 2014 and held it in 5 quarters. The position peaked at $840K in Q2 2015. 503 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Reynolds Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Reynolds Capital Management sold 4,100 Vertex Pharmaceuticals shares in Q1 2016, an estimated $516K.
Reynolds Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Reynolds Capital Management's Vertex Pharmaceuticals position peaked at $840K in Q2 2015.
503 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Reynolds Capital Management's 13F filing for Q1 2016, filed 13 May 2016.